When talking about people with hemophilia, use language that creates understanding, not pity, says columnist. Words matter.

Patients with hemophilia may experience clinically silent cerebral microbleeds that are associated with adverse outcomes including cognitive dysfunction. This study found associations between certain ...

Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study ...

Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding. Gene therapy for hemophilia B aims to establish sustained factor IX activity ...

There are several lab tests for hemophilia. However, the main tests detect the clotting activity of factors VIII and IX, which are proteins in the blood. Hemophilia is a bleeding disorder in which an ...

A recent study provides new insights into the mechanisms of coagulation in persons with haemophilia A, the most common form of haemophilia. The research team was able to show that saliva contains ...

Treatment with fidanacogene elaparvovec, a recombinant adeno-associated virus (AAV) vector developed for the treatment of hemophilia B, led to sustained expression of the high-activity factor IX ...

More people living with haemophilia A in the UK will be able to get access to a subcutaneous treatment, Roche/Chugai's Hemlibra, thanks to a decision by NHS England to make it an option for all ...

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety ...